caa a22 4500 469115904 CHVBK 20180323133124.0 cr unu---uuuuu 170328e19920901xx s 000 0 eng 10.1007/BF02735372 doi (NATIONALLICENCE)springer-10.1007/BF02735372 Double-blind randomized controlled trial and six-year open follow-up of yttrium-90 radiosynovectomy versus triamcinolone hexacetonide in persistent rheumatoid knee synovitis [Elektronische Daten] [E. Grant, N. Bellamy, K. Fryday-Field, T. Disney, A. Driedger, K. Hobby] Knee joints (n=30) from 22 adult rheumatoid arthritis (RA) patients who were previously randomized and subjected to a six-month double-blind controlled trial of yttrium-90 vs. triamcinolone hexacetonide with a six-year follow-up. In contrast to most previous studies, there was no co-administration of a steroid agent at the time the radiopharmaceutical was injected. One month after treatment the triamcinolone group had less pain (p<0.05), fewer effusions (p<0.001) and a better range of movement (p<0.01) than the yttrium group. Six months after treatment, the response in the triamcinolone group had partially regressed but was still superior to that of the yttrium group (p<0.05). At the six-year follow-up, half the yttrium-treated knees were found to have required treatment by intra-articular steroid, surgical synovectomy or total knee arthroplasty. The rates for therapeutic success were no different for yttrium-90 or triamcinolone. These results bring into question the reported efficacy of yttrium-90 and suggest that the benefit observed in clinical practice may be dependent upon the co-administration of a corticosteroid agent, and that the long-term benefits of yttrium may be relatively small. Kluwer Academic Publishers bv, 1992 uttrium nationallicence triamcinolone nationallicence rheumatoid arthritis nationallicence synovectomy nationallicence Grant E. Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada aut Bellamy N. Department of Medicine, University of Western Ontario, London, Ontario, Canada aut Fryday-Field K. Department of Medicine, University of Western Ontario, London, Ontario, Canada aut Disney T. Department of Medicine, University of Western Ontario, London, Ontario, Canada aut Driedger A. Department of Nuclear Medicine, University of Western Ontario, London, Ontario, Canada aut Hobby K. Department of Medicine, University of Western Ontario, London, Ontario, Canada aut InflammoPharmacology Springer Netherlands 1/3(1992-09-01), 231-238 0925-4692 1:3<231 1992 1 10787 https://doi.org/10.1007/BF02735372 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02735372 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Grant E. Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada aut NATIONALLICENCE 700 1- Bellamy N. Department of Medicine, University of Western Ontario, London, Ontario, Canada aut NATIONALLICENCE 700 1- Fryday-Field K. Department of Medicine, University of Western Ontario, London, Ontario, Canada aut NATIONALLICENCE 700 1- Disney T. Department of Medicine, University of Western Ontario, London, Ontario, Canada aut NATIONALLICENCE 700 1- Driedger A. Department of Nuclear Medicine, University of Western Ontario, London, Ontario, Canada aut NATIONALLICENCE 700 1- Hobby K. Department of Medicine, University of Western Ontario, London, Ontario, Canada aut NATIONALLICENCE 773 0- InflammoPharmacology Springer Netherlands 1/3(1992-09-01), 231-238 0925-4692 1:3<231 1992 1 10787 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer